GlassScriptPhysician profile
Kalidas G Sahetya
NPI 1649258088
$6,232.48
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,706 · 2020: $338 · 2021: $1,252 · 2022: $1,235 · 2023: $1,072 · 2024: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,485.95 | 2019-2024 | Xarelto |
| Terumo Medical Corporation | $925.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $563.44 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $529.63 | 2019-2024 | Lifevest |
| Pfizer INC. | $331.63 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $318.55 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $200.21 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.63 | 2019-2024 | Jardiance |
| Amgen INC. | $162.47 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $158.01 | 2019-2024 | Farxiga, Brilinta |
| Inspire Medical Systems, INC. | $134.03 | 2021 | |
| Phathom Pharmaceuticals, INC. | $118.00 | 2024 | Voquezna |
| Baxter Healthcare | $106.63 | 2023-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Harmony Biosciences LLC | $88.61 | 2020-2023 | Wakix |
| E.R. Squibb & Sons, L.L.C. | $84.56 | 2019-2023 | Eliquis |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $77.03 | 2020-2021 | |
| Abbvie INC. | $70.75 | 2021 | |
| Grifols USA, LLC | $61.49 | 2021-2022 | |
| Philips North America LLC | $61.27 | 2022-2024 | (Ck4) Mcot |
| Biohaven Pharmaceutical Holding Company LTD. | $58.14 | 2022 | |
| Mallinckrodt Hospital Products INC. | $57.80 | 2021 | |
| Glaxosmithkline, LLC. | $57.78 | 2022 | |
| Biotronik INC. | $56.88 | 2019 | |
| Bardy Diagnostics, INC. | $36.38 | 2020-2021 | |
| Angiodynamics, INC. | $31.14 | 2019-2021 | |
| Novo Nordisk INC | $27.52 | 2020-2021 | |
| Irhythm Technologies, INC. | $24.79 | 2022 | |
| Lundbeck LLC | $22.78 | 2020 | |
| Phadia US INC. | $20.79 | 2023 | Immunocap |
| Lilly USA, LLC | $18.04 | 2021 | |
| Advanced Respiratory, INC | $17.24 | 2021 | |
| Preventice Services, LLC | $16.67 | 2021 | |
| Elutia, INC. | $16.15 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.64 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.58 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.49 | 2022 | |
| Boston Scientific Corporation | $14.16 | 2022 | |
| Insmed, INC. | $13.14 | 2020 | |
| Pulmonx Corporation | $11.62 | 2021 | |
| Merck Sharp & Dohme LLC | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalidas Sahetya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.